Is LFMD or FLGT more profitable?

LifeMD has a net margin of 0.10% compared to Fulgent Genetics' net margin of -26.05%. Fulgent Genetics' return on equity of -4.93% beat LifeMD's return on equity. Company Net Margins Return on Equity Return on Assets LifeMD 0.10% -168.23% -31.27% Fulgent Genetics -26.05% -4.93% -4.50%

Does the media refer more to LFMD or FLGT?

In the previous week, Fulgent Genetics had 3 more articles in the media than LifeMD. MarketBeat recorded 5 mentions for Fulgent Genetics and 2 mentions for LifeMD. Fulgent Genetics' average media sentiment score of 0.89 beat LifeMD's score of 0.51 indicating that Fulgent Genetics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LifeMD 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Fulgent Genetics 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to SRTA or LFMD?

In the previous week, LifeMD had 1 more articles in the media than Strata Critical Medical. MarketBeat recorded 2 mentions for LifeMD and 1 mentions for Strata Critical Medical. LifeMD's average media sentiment score of 0.51 beat Strata Critical Medical's score of 0.00 indicating that LifeMD is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Strata Critical Medical 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral LifeMD 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend or LFMD?

LifeMD has a consensus target price of $7.57, suggesting a potential upside of 145.03%. Given LifeMD's stronger consensus rating and higher probable upside, analysts clearly believe LifeMD is more favorable than . Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 LifeMD 1 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.70

Which has better earnings and valuation, or LFMD?

LifeMD has higher revenue and earnings than . Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio N/A N/A N/A N/A N/A LifeMD $191.59M 0.78 $14.35M -$0.05 N/A

Is or LFMD more profitable?

LifeMD has a net margin of 0.10% compared to 's net margin of 0.00%. 's return on equity of 0.00% beat LifeMD's return on equity. Company Net Margins Return on Equity Return on Assets N/A N/A N/A LifeMD 0.10% -168.23% -31.27%

Does the media prefer or LFMD?

In the previous week, had 1388 more articles in the media than LifeMD. MarketBeat recorded 1390 mentions for and 2 mentions for LifeMD. LifeMD's average media sentiment score of 0.51 beat 's score of 0.00 indicating that LifeMD is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment 323 Very Positive mention(s) 328 Positive mention(s) 346 Neutral mention(s) 269 Negative mention(s) 124 Very Negative mention(s) Neutral LifeMD 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is SBC or LFMD more profitable?

SBC Medical Group has a net margin of 27.99% compared to LifeMD's net margin of 0.10%. SBC Medical Group's return on equity of 18.47% beat LifeMD's return on equity. Company Net Margins Return on Equity Return on Assets SBC Medical Group 27.99% 18.47% 13.10% LifeMD 0.10% -168.23% -31.27%

Does the media refer more to SBC or LFMD?

In the previous week, SBC Medical Group and SBC Medical Group both had 2 articles in the media. SBC Medical Group's average media sentiment score of 0.51 beat LifeMD's score of 0.51 indicating that SBC Medical Group is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment SBC Medical Group 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive LifeMD 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend LFMD or TACO?

LifeMD currently has a consensus price target of $7.57, indicating a potential upside of 145.03%. Given LifeMD's stronger consensus rating and higher probable upside, equities analysts plainly believe LifeMD is more favorable than Berto Acquisition. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score LifeMD 1 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.70 Berto Acquisition 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings & valuation, LFMD or TACO?

LifeMD has higher revenue and earnings than Berto Acquisition. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio LifeMD $191.59M 0.78 $14.35M -$0.05 N/A Berto Acquisition N/A N/A N/A N/A N/A

LifeMD (LFMD) Competitors

$3.09 +0.01 (+0.32%)

Closing price 09/8/2026 04:00 PM Eastern

Extended Trading

$3.14 +0.04 (+1.46%)

As of 09/8/2026 07:30 PM Eastern

Compare

LFMD vs. FLGT, SRTA, TOI, SBC, and TACO

Should you buy LifeMD stock or one of its competitors? LifeMD's main competitors and comparable companies include Fulgent Genetics (FLGT), Strata Critical Medical (SRTA), Oncology Institute (TOI), SBC Medical Group (SBC), and Berto Acquisition (TACO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare services" industry.

How does LifeMD compare to Fulgent Genetics?

LifeMD (NASDAQ:LFMD) and Fulgent Genetics (NASDAQ:FLGT) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, analyst recommendations, media sentiment, dividends, profitability and risk.

LifeMD has a beta of 2.04, indicating that its stock price is 104% more volatile than the broader market. Comparatively, Fulgent Genetics has a beta of 0.93, indicating that its stock price is 7% less volatile than the broader market.

LifeMD currently has a consensus price target of $7.57, suggesting a potential upside of 145.03%. Fulgent Genetics has a consensus price target of $27.50, suggesting a potential upside of 36.14%. Given LifeMD's stronger consensus rating and higher possible upside, research analysts clearly believe LifeMD is more favorable than Fulgent Genetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LifeMD	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70
Fulgent Genetics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

35.5% of LifeMD shares are held by institutional investors. Comparatively, 48.1% of Fulgent Genetics shares are held by institutional investors. 17.2% of LifeMD shares are held by company insiders. Comparatively, 36.2% of Fulgent Genetics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Fulgent Genetics had 3 more articles in the media than LifeMD. MarketBeat recorded 5 mentions for Fulgent Genetics and 2 mentions for LifeMD. Fulgent Genetics' average media sentiment score of 0.89 beat LifeMD's score of 0.51 indicating that Fulgent Genetics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
LifeMD	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Fulgent Genetics	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

LifeMD has higher earnings, but lower revenue than Fulgent Genetics. LifeMD is trading at a lower price-to-earnings ratio than Fulgent Genetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LifeMD	$191.59M	0.78	$14.35M	-$0.05	N/A
Fulgent Genetics	$322.67M	1.72	-$60.51M	-$2.82	N/A

LifeMD has a net margin of 0.10% compared to Fulgent Genetics' net margin of -26.05%. Fulgent Genetics' return on equity of -4.93% beat LifeMD's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LifeMD	0.10%	-168.23%	-31.27%
Fulgent Genetics	-26.05%	-4.93%	-4.50%

Summary

Fulgent Genetics beats LifeMD on 9 of the 16 factors compared between the two stocks.

How does LifeMD compare to Strata Critical Medical?

Strata Critical Medical (NASDAQ:SRTA) and LifeMD (NASDAQ:LFMD) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, media sentiment, analyst recommendations, risk, institutional ownership, profitability and earnings.

Strata Critical Medical has a beta of 2.26, suggesting that its stock price is 126% more volatile than the broader market. Comparatively, LifeMD has a beta of 2.04, suggesting that its stock price is 104% more volatile than the broader market.

Strata Critical Medical has higher revenue and earnings than LifeMD. Strata Critical Medical is trading at a lower price-to-earnings ratio than LifeMD, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Strata Critical Medical	$197.14M	2.38	$41.35M	-$0.04	N/A
LifeMD	$191.59M	0.78	$14.35M	-$0.05	N/A

47.4% of Strata Critical Medical shares are owned by institutional investors. Comparatively, 35.5% of LifeMD shares are owned by institutional investors. 15.5% of Strata Critical Medical shares are owned by company insiders. Comparatively, 17.2% of LifeMD shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, LifeMD had 1 more articles in the media than Strata Critical Medical. MarketBeat recorded 2 mentions for LifeMD and 1 mentions for Strata Critical Medical. LifeMD's average media sentiment score of 0.51 beat Strata Critical Medical's score of 0.00 indicating that LifeMD is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Strata Critical Medical	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
LifeMD	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Strata Critical Medical has a net margin of 15.71% compared to LifeMD's net margin of 0.10%. Strata Critical Medical's return on equity of -2.97% beat LifeMD's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Strata Critical Medical	15.71%	-2.97%	-2.54%
LifeMD	0.10%	-168.23%	-31.27%

Strata Critical Medical presently has a consensus price target of $8.00, indicating a potential upside of 50.66%. LifeMD has a consensus price target of $7.57, indicating a potential upside of 145.03%. Given LifeMD's higher possible upside, analysts plainly believe LifeMD is more favorable than Strata Critical Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Strata Critical Medical	0 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.75
LifeMD	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70

Summary

Strata Critical Medical beats LifeMD on 11 of the 17 factors compared between the two stocks.

How does LifeMD compare to ?

(:) and LifeMD (NASDAQ:LFMD) are related companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, risk, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations.

In the previous week, had 1388 more articles in the media than LifeMD. MarketBeat recorded 1390 mentions for and 2 mentions for LifeMD. LifeMD's average media sentiment score of 0.51 beat 's score of 0.00 indicating that LifeMD is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
	323 Very Positive mention(s)	328 Positive mention(s)	346 Neutral mention(s)	269 Negative mention(s)	124 Very Negative mention(s)	Neutral
LifeMD	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

LifeMD has a consensus target price of $7.57, suggesting a potential upside of 145.03%. Given LifeMD's stronger consensus rating and higher probable upside, analysts clearly believe LifeMD is more favorable than .

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
LifeMD	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70

LifeMD has higher revenue and earnings than .

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
	N/A	N/A	N/A	N/A	N/A
LifeMD	$191.59M	0.78	$14.35M	-$0.05	N/A

35.5% of LifeMD shares are owned by institutional investors. 17.2% of LifeMD shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

LifeMD has a net margin of 0.10% compared to 's net margin of 0.00%. 's return on equity of 0.00% beat LifeMD's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
	N/A	N/A	N/A
LifeMD	0.10%	-168.23%	-31.27%

Summary

LifeMD beats on 8 of the 11 factors compared between the two stocks.

How does LifeMD compare to SBC Medical Group?

SBC Medical Group (NASDAQ:SBC) and LifeMD (NASDAQ:LFMD) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, valuation, risk, dividends, earnings, analyst recommendations, institutional ownership and media sentiment.

SBC Medical Group presently has a consensus price target of $8.50, indicating a potential upside of 91.87%. LifeMD has a consensus price target of $7.57, indicating a potential upside of 145.03%. Given LifeMD's stronger consensus rating and higher possible upside, analysts clearly believe LifeMD is more favorable than SBC Medical Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SBC Medical Group	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
LifeMD	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70

SBC Medical Group has a net margin of 27.99% compared to LifeMD's net margin of 0.10%. SBC Medical Group's return on equity of 18.47% beat LifeMD's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SBC Medical Group	27.99%	18.47%	13.10%
LifeMD	0.10%	-168.23%	-31.27%

60.8% of SBC Medical Group shares are held by institutional investors. Comparatively, 35.5% of LifeMD shares are held by institutional investors. 81.7% of SBC Medical Group shares are held by company insiders. Comparatively, 17.2% of LifeMD shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

SBC Medical Group has a beta of 0.63, meaning that its stock price is 37% less volatile than the broader market. Comparatively, LifeMD has a beta of 2.04, meaning that its stock price is 104% more volatile than the broader market.

SBC Medical Group has higher earnings, but lower revenue than LifeMD. LifeMD is trading at a lower price-to-earnings ratio than SBC Medical Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SBC Medical Group	$175.17M	2.60	$50.99M	$0.47	9.43
LifeMD	$191.59M	0.78	$14.35M	-$0.05	N/A

In the previous week, SBC Medical Group and SBC Medical Group both had 2 articles in the media. SBC Medical Group's average media sentiment score of 0.51 beat LifeMD's score of 0.51 indicating that SBC Medical Group is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SBC Medical Group	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
LifeMD	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

SBC Medical Group beats LifeMD on 10 of the 15 factors compared between the two stocks.

How does LifeMD compare to Berto Acquisition?

LifeMD (NASDAQ:LFMD) and Berto Acquisition (NASDAQ:TACO) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, earnings, profitability, risk, analyst recommendations, valuation, dividends and media sentiment.

35.5% of LifeMD shares are held by institutional investors. 17.2% of LifeMD shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

LifeMD currently has a consensus price target of $7.57, indicating a potential upside of 145.03%. Given LifeMD's stronger consensus rating and higher probable upside, equities analysts plainly believe LifeMD is more favorable than Berto Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LifeMD	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70
Berto Acquisition	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

LifeMD has a net margin of 0.10% compared to Berto Acquisition's net margin of 0.00%. Berto Acquisition's return on equity of 0.00% beat LifeMD's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LifeMD	0.10%	-168.23%	-31.27%
Berto Acquisition	N/A	N/A	N/A

LifeMD has higher revenue and earnings than Berto Acquisition.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LifeMD	$191.59M	0.78	$14.35M	-$0.05	N/A
Berto Acquisition	N/A	N/A	N/A	N/A	N/A

In the previous week, LifeMD had 2 more articles in the media than Berto Acquisition. MarketBeat recorded 2 mentions for LifeMD and 0 mentions for Berto Acquisition. LifeMD's average media sentiment score of 0.51 beat Berto Acquisition's score of 0.00 indicating that LifeMD is being referred to more favorably in the media.

Company	Overall Sentiment
LifeMD	Positive
Berto Acquisition	Neutral

LifeMD has a beta of 2.04, suggesting that its share price is 104% more volatile than the broader market. Comparatively, Berto Acquisition has a beta of 0.08, suggesting that its share price is 92% less volatile than the broader market.

Summary

LifeMD beats Berto Acquisition on 10 of the 12 factors compared between the two stocks.

Get LifeMD News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LFMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LFMD vs. The Competition

Export

Metric	LifeMD	Healthcare Providers & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$148.46M	$10.01B	$7.39B	$12.89B
Dividend Yield	N/A	2.59%	2.54%	9.14%
P/E Ratio	-61.79	34.35	270.65	25.39
Price / Sales	0.78	4.90	611.04	82.71
Price / Cash	N/A	121.42	77.07	52.39
Price / Book	6.44	5.33	10.92	6.40
Net Income	$14.35M	$313.25M	$3.48B	$358.18M
7 Day Performance	0.65%	-0.14%	-0.87%	0.07%
1 Month Performance	-13.20%	-0.85%	3.01%	-0.78%
1 Year Performance	-49.18%	15.15%	22.26%	12.49%

LifeMD Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LFMD LifeMD	3.3937 of 5 stars	$3.09 +0.3%	$7.57 +145.0%	-49.8%	$148.46M	$191.59M	N/A	230	News Coverage
FLGT Fulgent Genetics	3.1773 of 5 stars	$19.37 -1.2%	$27.50 +42.0%	-9.3%	$539.58M	$322.67M	N/A	1,315	Positive News
SRTA Strata Critical Medical	1.9759 of 5 stars	$5.66 -5.2%	$8.00 +41.3%	N/A	$528.15M	$197.14M	N/A	130	Positive News
TOI Oncology Institute	N/A	$5.19 +1.1%	$8.50 +63.9%	N/A	$512.58M	$545.76M	N/A	660	Gap Down
SBC SBC Medical Group	4.2194 of 5 stars	$4.02 -0.7%	$8.50 +111.4%	-11.2%	$416.53M	$173.61M	8.55	N/A

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LFMD) was last updated on 9/9/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

LifeMD (LFMD) Competitors

LFMD vs. FLGT, SRTA, TOI, SBC, and TACO

How does LifeMD compare to Fulgent Genetics?

Summary

How does LifeMD compare to Strata Critical Medical?

Summary

How does LifeMD compare to ?

Summary

How does LifeMD compare to SBC Medical Group?

Summary

How does LifeMD compare to Berto Acquisition?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LFMD vs. The Competition

LifeMD Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

LifeMD (LFMD) Competitors

LFMD vs. FLGT, SRTA, TOI, SBC, and TACO

How does LifeMD compare to Fulgent Genetics?

Which has more risk and volatility, LFMD or FLGT?

Do analysts prefer LFMD or FLGT?

Do insiders & institutionals have more ownership in LFMD or FLGT?

Does the media refer more to LFMD or FLGT?

Which has preferable earnings and valuation, LFMD or FLGT?

Is LFMD or FLGT more profitable?

Summary

How does LifeMD compare to Strata Critical Medical?

Which has more risk and volatility, SRTA or LFMD?

Which has preferable earnings & valuation, SRTA or LFMD?

Do insiders & institutionals hold more shares of SRTA or LFMD?

Does the media refer more to SRTA or LFMD?

Is SRTA or LFMD more profitable?

Do analysts prefer SRTA or LFMD?

Summary

How does LifeMD compare to ?

Does the media prefer or LFMD?

Do analysts recommend or LFMD?

Which has better earnings and valuation, or LFMD?

Do insiders & institutionals have more ownership in or LFMD?

Is or LFMD more profitable?

Summary

How does LifeMD compare to SBC Medical Group?

Do analysts prefer SBC or LFMD?

Is SBC or LFMD more profitable?

Do insiders & institutionals believe in SBC or LFMD?

Which has more volatility and risk, SBC or LFMD?

Which has better valuation and earnings, SBC or LFMD?

Does the media refer more to SBC or LFMD?

Summary

How does LifeMD compare to Berto Acquisition?

Do institutionals and insiders hold more shares of LFMD or TACO?

Do analysts recommend LFMD or TACO?

Is LFMD or TACO more profitable?

Which has better earnings & valuation, LFMD or TACO?

Does the media prefer LFMD or TACO?

Which has more volatility & risk, LFMD or TACO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LFMD vs. The Competition

LifeMD Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools